Most Recent Posts
Today was the launch of the Script Your Future campaign, an effort to encourage patients living with chronic diseases to better manage their conditions by taking their medicines as directed.
According to the campaign's Web site, "Understanding your condition and taking your medicine correctly are important steps toward a longer, healthier life. This campaign can help you with tools to manage your medicines."
A piece over at Everyday Health has some good, common sense tips for women concerned about heart disease.
Last Wednesday, I mentioned a Boston Globe article about biopharmaceutical research companies and the emphasis on studying medicines in specific populations, for rare conditions, and more.
In that post, I provided some examples of PhRMA's Medicines in Development Reports, which are a wealth of just this sort of information.
I've got a couple of more good pieces I want to pass along today.
Tonight, the Society for Women's Health Research is hosting an event to raise awareness about the health needs of women who have served in the armed forces.
"Beyond the Camouflage: Uncovering the Health Needs of Women Veterans" will focus on - and celebrate - the nearly 2 million women veterans and 230,000 women deployed to Iraq and Afghanistan."
A recent study in the Journal of the American Medical Association raises notable points about the current presence of comparative effectiveness research (CER) in the health care system.
Excluding orphan drugs and first-in-class medicines, a majority of new medicines (defined as new molecular entities) approved by the FDA between 2000 and 2010 had CER data available at the time of approval.
With the debate over the future of Medicare heating up, there are two interesting recent opinion pieces worth taking a look at.
An article in today's Boston Globe refers to biopharmaceutical research companies "dedicating more resources to rare disorders, illnesses that are prevalent in the developing world, and medical conditions that affect minority populations in rich countries."
The devastation caused by the string of tornadoes and storms continues to be felt. We've already blogged a couple of times on what Rx Response is doing to assist state and local emergency managers. But circumstances call for additional help for many of the region's uninsured patients, and the Partnership for Prescription Assistance is also stepping in to help.
For years, PhRMA has supported several programs that educate consumers about the safe disposal of expired and unused medications, including SMARxT Disposal, American Medicine Chest Challenge, and most recently, the DEA National Take Back Day, which occurred April 30 at approved locations across the nation.
As a result of the string of deadly tornadoes that have ravaged the Southeast United States, Rx Response began immediately monitoring the storms' impact on the flow of medicine in the affected areas and has elevated its engagement status from Stand-By to Alert.
Walmart, the nation's largest retailer, recently joined SMARxT Disposal, a program that helps educate customers about the proper way to quickly and safely dispose of any unused prescription drugs. Walmart will launch the national educational program in more than 3,500 of their pharmacies.
Douglas Peddicord, Ph.D., has an interesting blog post on the high quality of clinical trials conducted around the world in the Huffington Post.
Two weeks ago at our annual meeting, attendees heard a variety of governors talk about the roles that biopharmaceutical research companies play in their state economies. Now, a new resource on PhRMA's website makes it easier for the public to see this role.
The Huffington Post has an interesting piece today that's worth reading on new efforts to research and develop new medicines to treat rare diseases. Of course, many of these efforts aren't really new. America's biopharmaceutical research companies have long researched and developed medicines targeting rare diseases (i.e. conditions affecting less than 200,000 patients).
A few weeks ago, the indomitable Jennifer Windrum, of WTF: Where's The Funding? (for lung cancer), asked me to write a guest post for her blog. I was honored, and saw it as a great opportunity to reach cancer patients who may not know just how much work is going into research and development for new medicines to potentially treat the countless cancers that plague so many Americans.
Sunday's Boston Globe included a multi-part series detailing Cambridge, Mass.-based Vertex Pharmaceuticals, Inc., a growing biopharmaceutical firm that is hoping to find itself on the cusp of moving from a young start-up to a commercially viable company. In this sense, it's a great example of the many emerging companies that contribute to the work done throughout the biopharmaceutical research sector, and we'll continue to highlight similar emerging companies in the future here on The Catalyst.